AU2003265873A1 - Oncolytic adenoviral vectors encoding gm-csf - Google Patents
Oncolytic adenoviral vectors encoding gm-csfInfo
- Publication number
- AU2003265873A1 AU2003265873A1 AU2003265873A AU2003265873A AU2003265873A1 AU 2003265873 A1 AU2003265873 A1 AU 2003265873A1 AU 2003265873 A AU2003265873 A AU 2003265873A AU 2003265873 A AU2003265873 A AU 2003265873A AU 2003265873 A1 AU2003265873 A1 AU 2003265873A1
- Authority
- AU
- Australia
- Prior art keywords
- csf
- adenoviral vectors
- vectors encoding
- oncolytic adenoviral
- oncolytic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title 1
- 230000000174 oncolytic effect Effects 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2003/027380 WO2005030261A1 (en) | 2003-08-28 | 2003-08-28 | Oncolytic adenoviral vectors encoding gm-csf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003265873A1 true AU2003265873A1 (en) | 2005-04-14 |
Family
ID=34392797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003265873A Abandoned AU2003265873A1 (en) | 2003-08-28 | 2003-08-28 | Oncolytic adenoviral vectors encoding gm-csf |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003265873A1 (en) |
| WO (1) | WO2005030261A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11896635B2 (en) | 2017-11-08 | 2024-02-13 | Kagoshima University | Oncolytic virus (oncolytic immunotherapy) capable of effectively treating even metastatic cancer while ensuring safety, with expression control system providing optimal expression level of mounted immunogenic gene |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2379586T3 (en) * | 2008-12-22 | 2017-02-06 | Targovax Oy | Oncolytic adenoviral vectors and methods and applications associated therewith |
| US9345787B2 (en) | 2008-12-22 | 2016-05-24 | Targovax Oy | Adenoviral vectors and methods and uses related thereto |
| FI20090030A0 (en) * | 2009-02-02 | 2009-02-02 | Akseli Eetu Hemminki | Oncolytic virus |
| JP6576326B2 (en) | 2013-03-14 | 2019-09-18 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Oncolytic adenovirus composition |
| ES2933174T3 (en) | 2016-02-23 | 2023-02-02 | Salk Inst For Biological Studi | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| ES3041500T3 (en) | 2016-03-10 | 2025-11-12 | Cg Oncology Inc | Methods of treating solid tumors by combination therapy |
| JP2019536468A (en) | 2016-12-12 | 2019-12-19 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Synthetic adenovirus targeting tumors and uses thereof |
| JP2020516590A (en) | 2017-04-14 | 2020-06-11 | コールド ジェネシス, インコーポレイテッド | How to treat bladder cancer |
| CN109207437B (en) * | 2017-07-07 | 2022-03-11 | 乾元浩生物股份有限公司 | Group I8 avian adenovirus strain and application thereof |
| KR20200140848A (en) | 2018-04-09 | 2020-12-16 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Oncolytic adenovirus composition with improved replication properties |
| CN118853767A (en) * | 2024-08-22 | 2024-10-29 | 华中科技大学同济医学院附属同济医院 | A novel oncolytic adenovirus vector and its construction method and application |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2380537C (en) * | 1999-11-15 | 2011-01-18 | Onyx Pharmaceuticals, Inc. | An oncolytic adenovirus |
| EP1377672A2 (en) * | 2001-02-23 | 2004-01-07 | Novartis AG | Vector constructs |
| IL152420A0 (en) * | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
| AU2003261076A1 (en) * | 2002-06-07 | 2003-12-22 | Novartis Ag | Assay to detect replication competent viruses |
-
2003
- 2003-08-28 AU AU2003265873A patent/AU2003265873A1/en not_active Abandoned
- 2003-08-28 WO PCT/US2003/027380 patent/WO2005030261A1/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11896635B2 (en) | 2017-11-08 | 2024-02-13 | Kagoshima University | Oncolytic virus (oncolytic immunotherapy) capable of effectively treating even metastatic cancer while ensuring safety, with expression control system providing optimal expression level of mounted immunogenic gene |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005030261A1 (en) | 2005-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003295502A1 (en) | Adenoviral vector vaccine | |
| AU2003208517A1 (en) | Switching between coding schemes | |
| GB0325379D0 (en) | Vectors | |
| AU2003238456A1 (en) | Viral vector | |
| AU2002305427A1 (en) | Airtight magnetic applicator system | |
| AU2003266879A1 (en) | Improved dense mode coding scheme | |
| AU2002952873A0 (en) | Image encoding system | |
| AU2003280486A1 (en) | Computationally constrained video encoding | |
| AU2003265873A1 (en) | Oncolytic adenoviral vectors encoding gm-csf | |
| GB0229696D0 (en) | Separation medium | |
| AU2003278695A1 (en) | Nucleic acid vectors | |
| AU2003901876A0 (en) | Viral vector | |
| AU2002360353A1 (en) | Receptor-targeted adenoviral vectors | |
| AU2002326720A1 (en) | Genes encoding carotenoid compounds | |
| AU2003259782A1 (en) | Noise-adaptive decoding | |
| AU2003288684A1 (en) | Video coding | |
| EP1390476A4 (en) | Mosaic adenoviral vectors | |
| AU2003271883A1 (en) | Vector system | |
| AU2003251370A1 (en) | Chromatographic medium | |
| AU2003241268A1 (en) | Adenoviral vector with replication-dependent transgene expression | |
| AU2002342536A1 (en) | Adenoviral vector system | |
| GB2405560B (en) | Vector quantization | |
| AU2003229942A1 (en) | Sfr2 protein encoding gene | |
| HK1079550A (en) | Adenoviral vector vaccine | |
| AU2003253447A1 (en) | Expression vectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |